Compare Amphastar Pharmaceuticals Inc (AMPH) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Oxford Lane Capital Corp trades at $9.34 (market cap $905.21M). The key difference: Amphastar Pharmaceuticals Inc and Oxford Lane Capital Corp are close in size by market cap, and Oxford Lane Capital Corp pays a 25.89% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | OXLC | |
|---|---|---|
Market Cap | $863.95M | $905.21M |
Sector | Health | Financials |
52-Week High | $30.81 | $18.75 |
52-Week Low | $16.87 | $8.15 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 25.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
OXLC trades at $9.20, up 0.44% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock's valuation shows a low price-to-book ratio of 0.88, yet profitability metrics are deeply negative with an ROE of -39.16%. Recent earnings have consistently missed expectations, and the company has declared a series of $0.20 dividends through 2026. Cash flow from operations was negative $703.80M in 2025, offset by financing activities.
The outlook is clouded by severe fundamental deterioration, including a projected revenue collapse and net loss for 2026. While the high dividend yield and discounted P/B may attract some investors, the risks from unsustainable distributions, declining net asset value, and negative returns on equity warrant extreme caution. Analyst sentiment is mixed, reflecting the stock's high-risk, high-yield profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
